|
The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Portola Pharmaceuticals |
Research Funding - Kite, a Gilead company (Inst); Seagen (Inst) |
Patents, Royalties, Other Intellectual Property - Patient on bone marrow microenvironment signals (I) |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche; Takeda |
Speakers' Bureau - Takeda |
Travel, Accommodations, Expenses - Takeda |
|
|
Research Funding - Amgen (Inst); Janssen (Inst); Novartis (Inst) |
|
|
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Varian Medical Systems (Inst) |
Travel, Accommodations, Expenses - Elekta |
|
|
Honoraria - Bristol-Myers Squibb; Celgene; Genmab; Incyte; Kite, a Gilead company; Kymera; MorphoSys; Novartis; Takeda |
Consulting or Advisory Role - Boehringer Ingelheim; Epizyme; Janssen; Oncimmune |
Research Funding - Epizyme (Inst) |
Patents, Royalties, Other Intellectual Property - Combined use of Fc gamma RIIb (CD32b) and CD20 - specific antibodies. WO Patent, PCT/GB2011/051572; EU11760819.0 |
|
|
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; AstraZeneca; Bayer; BeiGene; Celgene; Genentech; Janssen; Juno Therapeutics; Kite/Gilead; MEI Pharma; MorphoSys; Pharmacyclics; Pharmacyclics; Roche; TG Therapeutics |
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Celgene (Inst); Genentech (Inst) |
Travel, Accommodations, Expenses - Abbvie; Celgene; Genentech/Roche; Juno Therapeutics; Millennium; Seagen |
|
|
No Relationships to Disclose |
|
|
Research Funding - Merck (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - AstraZeneca (I); GlaxoSmithKline (I) |
Honoraria - ADC Therapeutics; Takeda |
Consulting or Advisory Role - Novartis; Seagen; Takeda |
Speakers' Bureau - Novartis; Seagen; Takeda |
Research Funding - Takeda |
Travel, Accommodations, Expenses - ADC Therapeutics; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Tufts Medical Center |
Consulting or Advisory Role - Abbvie; Alnylam; Merck; Novartis; Precision Health Economics; Sage Therapeutics; Vertex |
Research Funding - AdvaMed (Inst); Bluebird Bio (Inst); Genentech (Inst); Lundbeck (Inst) |
|
|
Honoraria - Affimed Therapeutics; Bayer; Cota Healthcare; Epizyme; Miltenyi Biotec; MorphoSys; Novartis; Pharmacyclics; Research to Practice; Seagen; Verastem; Verastem |
Consulting or Advisory Role - Affimed Therapeutics; Bayer; Cota Healthcare; Epizyme; Miltenyi Biotec; MorphoSys; Novartis; Pharmacyclics; Seagen; Verastem |
Research Funding - Tesaro |
Travel, Accommodations, Expenses - Affimed Therapeutics; Bayer; Novartis; Pharmacyclics; Research to Practice; Seagen; Verastem |